US20150045298A1 - Composition including stem cell-derived microvesicles for promoting neurogenesis - Google Patents

Composition including stem cell-derived microvesicles for promoting neurogenesis Download PDF

Info

Publication number
US20150045298A1
US20150045298A1 US14/238,798 US201214238798A US2015045298A1 US 20150045298 A1 US20150045298 A1 US 20150045298A1 US 201214238798 A US201214238798 A US 201214238798A US 2015045298 A1 US2015045298 A1 US 2015045298A1
Authority
US
United States
Prior art keywords
stem cells
microvesicles
cells
derived microvesicles
ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/238,798
Other languages
English (en)
Inventor
Oh Young Bang
Gyeong Joon Moon
Yeon Hee Cho
Suk Jae Kim
Dong Hee Kim
Ji Hee Sung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Life Public Welfare Foundation
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Assigned to SAMSUNG LIFE PUBLIC WELFARE FOUNDATION reassignment SAMSUNG LIFE PUBLIC WELFARE FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, SUK JAE, BANG, OH YOUNG, KIM, DONG HEE, MOON, Gyeong Joon, CHO, YEON HEE, SUNG, JI Hee
Publication of US20150045298A1 publication Critical patent/US20150045298A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Definitions

  • the present invention relates to a composition comprising stem cell-derived microvesicles for promoting neurogenesis and a method for promoting neurogenesis.
  • stem cell therapies have been conducted for various diseases such as cerebral infarction, traumatic neuronal injury, musculoskeletal disease, etc.
  • the current technology has reached up to the level of simple extraction, culture and proliferation of stem cells and injection of the stem cells.
  • stem cell therapies have not yet shown a significant effect. Extensive research on a variety of genetically modified stem cells to promote the effect has continued to progress, but cell therapies using genes cannot be applied to the human body due to ethical issues.
  • stem cells there are several problems in clinical application of the use of stem cells. Firstly, in the case of cell therapy products, there is a risk of tumor formation after stem cells are transplanted into tissue. Secondly, stem cells may cause arterial occlusion due to a relatively large size, resulting in cerebral infarction. Thirdly, stem cells can migrate to the brain during the acute phase when the brain-blood barrier is open but have limitations in crossing the brain-blood barrier due to a large size during the chronic stage. Lastly, inducing stem cells to specialized cells having desired properties for cell therapy products has limitation.
  • microvesicles are small vesicles of 0.1to 1 ⁇ m diameter and refer to cell membrane microparticles circulating in the blood, such as endothelial cells, platelets, etc. It is known that stem cell-derived microvesicles contain proteins, receptors as well as nuclear components and thus have a role in cell-to-cell communication. Moreover, the microvesicles contain a relatively small amount of animal serum compared to stem cells, and the risk of zoonosis can also be eliminated. In view of these characteristics of microvesicles, the cell therapy using microvesicles is expected to be a new paradigm that can overcome the limitations of existing stem cell therapies.
  • WO 2010/070141 discloses a method for producing stem cell-derived microvesicles and therapeutic effects of the produced microvesicles on immune disease, allergic response, inflammatory disease, etc.
  • Korean Patent Publication No. 2010-122027 discloses a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell and a technology using the particle as a therapeutic agent for cardioprotection.
  • the present inventors have studied the correlation between microvesicles and neuronal cells and found that stem cell-derived microvesicles have excellent effects of promoting neurogenesis and migration of neuronal cells and promoting angiogenesis in vascular endothelial cells, thus completing the present invention.
  • the present invention provides a composition for promoting neurogenesis, comprising stem cell-derived microvesicles as an active ingredient.
  • the present invention provides a method for promoting neurogenesis, comprising the step of applying stem cell-derived microvesicles to neural stem cells.
  • the present invention provides a pharmaceutical composition for prevention or treatment of degenerative neurological diseases, comprising stem cell-derived microvesicles as an active ingredient.
  • the present invention provides a method for treating neurological damage, comprising the step of treating a subject other than human, suffering from neurological damage, with stem cell-derived microvesicles.
  • the stem cell-derived microvesicles according to the present invention have excellent effects of promoting neurogenesis and migration of neuronal cells and promoting angiogenesis of vascular endothelial cells, thus treating neurological damage.
  • FIG. 1 shows blood levels of CD105-positive/annexin V-negative and CXCR4-positive/annexin V-negative microvesicles in a patient with a small infarct (A) and in a patient with a large infarct (B) and the correlation between CD105-positive and CD90-positive (C).
  • FIG. 2 shows the correlation between CD105-positive/annexin V-negative microvesicles (A), CD105-positive/CXCR4-positive/annexin V-negative microvesicles (B), and SDF-1 ⁇ (C) according to the infarct size (DWI), NIHSS, and the time since the onset of cerebral infarction.
  • A CD105-positive/annexin V-negative microvesicles
  • B CD105-positive/CXCR4-positive/annexin V-negative microvesicles
  • C SDF-1 ⁇
  • FIG. 3 shows the numbers of stem cell-derived microvesicles in bone marrow-derived mesenchymal stem cells treated with Kn DEME (knockout DEME), STS 100 nm (staurosporin A), 20% ischemic brain extract (20% BE (whole)), and 20% ischemic serum (20% serum), determined by a flow cytometer using CD105 and annexin V.
  • FIG. 4 shows neuronal cell deaths atter treatment of neuronal cells with stem cell-derived microvesicles (1, 3, 10, 30 ⁇ g/ml) obtained by ischemic stimuli or with 30 ⁇ m NMDA as a control, determined by LDH analysis.
  • FIG. 5 shows neurogenesis capabilities after treatment of neuronal stem cells with microvesicles obtained without ischemic stimuli (A) or with stem cell-derived microvesicles obtained by ischemic stimuli (B), determined by an optical microscope and a confocal microscope.
  • FIG. 6 shows angiogenesis capabilities of vascular endothelial cells after treatment with microvesicles (1, 3, 10, 30 ⁇ m/ml) obtained by ischemic stimuli, determined by a fluorescence microscope.
  • FIG. 7 shows migration distances of neural progenitor cells after injection of microvesicles obtained by ischemic stimuli into the ventricle of rats with ischemic stroke, determined by fluorescence staining (A) and shows the numerical results thereof (B) (Contra: contralateral, ipsi: ipsilateral).
  • FIG. 8 shows angiogenesis of vascular endothelial cells after injection of stem cell-derived microvesicles obtained by ischemic stimuli into the ventricle of rats with ischemic stroke, determined by fluorescence staining (A) and shows the numerical results thereof (B) (Contra: contralateral, ipsi: ipsilateral, sham: normal control group).
  • the present invention provides a composition for promoting neurogenesis, comprising stem cell-derived microvesicles as an active ingredient.
  • the present invention provides a method for promoting neurogenesis, comprising the step of applying stem cell-derived microvesicles to neural stem cells.
  • stem cell-derived microvesicles refers to small vesicles derived from stem cells, containing receptors and proteins, and having a diameter of 0.1 to 1 ⁇ m.
  • the stem cell-derived microvesicles may be microvesicles derived from stem cells induced by ischemic stimuli, and the ischemic stimuli may preferably be ischemic preconditioning stimuli.
  • the ischemic preconditioning stimuli may be performed by exposing stem cells to an environment that causes ischemia or treating stem cells with ischemic brain extract.
  • the ischemic brain extract may be an extract obtained from the brain of subjects that have ischemic symptoms.
  • the one example of ischemic symptoms may be ischemic stroke.
  • the stem cell-derived microvesicles may include, but not particularly limited to, CD105 positive microvesicles, annexin V-negative microvesicles, etc. which are specific to mesenchymal stem cells
  • the stem cells that are the source of the microvesicles may be, but not limited to, any one of induced pluripotent stem cells (iPS), adult stem cells, embryonic stem cells, mesenchymal stem cells, adipose stem cells, hematopoietic stem cells, and cord blood stem cells, preferably mesenchymal stem cells.
  • iPS induced pluripotent stem cells
  • adult stem cells embryonic stem cells
  • mesenchymal stem cells adipose stem cells
  • hematopoietic stem cells hematopoietic stem cells
  • cord blood stem cells preferably mesenchymal stem cells.
  • the stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of neuronal cells and also promote angiogenesis in vascular endothelial cells.
  • the present invention provides a pharmaceutical composition for prevention or treatment of degenerative: neurological diseases, comprising stem cell-derived microvesicles as an active ingredient.
  • the stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of neuronal cells and promote angiogenesis in vascular endothelial cells, thus having excellent effect of treating neurological damage. Therefore, the stem cell-derived microvesicles according to the present invention can be effectively used in prevention or treatment of degenerative neurological diseases.
  • degenerative neurological diseases is intended to include, but not limited to, a variety of diseases caused by neurological damage without limitation, and an example of the degenerative neurological diseases may be any one of ischemic stroke, cerebral infarction, neurotrauma, Parkinson's disease, Lou Gehrig' disease, and epilepsy.
  • the pharmaceutical composition for prevention or treatment of degenerative neurological diseases comprising stem cell-derived microvesicles as an active ingredient according to the present invention may preferably contain other ingredients which may provide a synergy effect to the main effect within a range of not impairing the main effect of the present invention, in addition to the stem cell-derived microvesicles.
  • the pharmaceutical composition of the present invention may further comprise pharmaceutically acceptable carrier, excipients, and diluents for administration, in addition to the above-described active ingredient.
  • carriers, excipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • the pharmaceutical composition of the present invention may be formulated into various formulations for parenteral or oral administration.
  • a representative example of the parenteral formulation may preferably be an isotonic aqueous solution or as an injectable formulation.
  • the injectable formulation may be prepared by a method known in the art using a suitable dispersant or wetting agent and a suspending agent by any method known in the art.
  • the respective ingredients may be dissolved in a saline or buffer solution to be formulated into an injectable formulation.
  • Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, etc.
  • the solid formulations may be prepared by mixing the active ingredient with at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • lubricants such as magnesium stearate, talc, etc. may be used in addition to simple excipients.
  • Liquid formulations for oral administration may include suspensions, internal solutions, emulsions, syrups, etc.
  • the liquid formulations may include, and various excipients such as humectants, sweeteners, aromatics, preservatives, etc. may be included in addition to generally-used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration may include sterile solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable it such as olive oil, and injectable ester such as ethyl oleate, etc. may be used for non-aqueous solvents and suspensions.
  • Witepsol, macrogol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc. may be used for suppository bases.
  • the effective dosage of the pharmaceutical composition of the present invention may vary depending on the age, gender, and weight of a patient.
  • the pharmaceutical composition of the present invention may be administered in a dose of 100 ⁇ g/kg to 1 mg/kg, preferably 200 ⁇ g/kg to 500 ⁇ g/kg.
  • composition of the present invention may be used alone or in combination with surgical operation, chemical therapy, radiotherapy, hormonal therapy, chemical therapy, drug therapy, and methods using biological response modifiers.
  • the present invention provides a method for treating neurological damage, comprising the step of treating a subject other than human, suffering from neurological damage, with stem cell-derived microvesicles.
  • the treatment with stem cell-derived microvesicles promotes neurogenesis and migration of neuronal cells and also promotes angiogenesis in vascular endothelial cells, thus effectively treating neurological damage.
  • the term “neurological damage” refers to damage to the nerve caused by physical factors or degenerative neurological diseases.
  • the neurological damage by physical factors may include, but not limited to, brain trauma, spinal cord injury, cerebral infarction, cerebral hemorrhage, neurotrauma, etc.
  • the neurological damage by degenerative neurological disease may include, but not limited to, ischemic stroke, cerebral infarction, neurotrauma, Parkinson's disease, Lou Gehrig' disease, and epilepsy.
  • the subject other than human may preferably include, but not limited to, a rat, a red fox, a skunk, a raccoon, a badger, a dog, a wolf, a mongoose, a coyote, a weasel, and a cat.
  • FIG. 1 it was found that the amount of CD105-positive cells and CXCR4-positive cells in patients with a large infarct (B) after the onset of cerebral infarction was greater than that in patients with a small infarct (A). It can be seen from this result that the number of stem cell-derived microvesicles and microvesicles capable of migrating by SDF-1 chemotaxis increases in patients with a large infarct. Moreover, it was found that most CD105-positive cells were CD90 double-positive cells, indicating that CD105-positive microvesicles were derived from stem cells.
  • the number of CD105-positive/annexin V-negative stem cell-derived microvesicles showed a tendency to increase as the infarct size was larger and the NIHSS score was higher (A)
  • the number of CD105-positive/CXCR4-positive/annexin V-negative microvesicles showed a tendency to increase as the NIHSS score was higher and to decrease as the time since the onset of cerebral infarction increased (B).
  • the blood level of stem cells with high motility was increased by microvesicles as the severity of cerebral infarction was higher, indicating that the existence of potential stem cells may decrease as the time since the onset of cerebral infarction increases.
  • the blood concentration of SDF-1 ⁇ decreased as the infarct size was larger and increased as the time since the onset of cerebral infarction increased (C).
  • Bone marrows were collected from the femur of rats to obtain bone marrow-derived mesenchymal stem cells by culture.
  • the obtained mesenchymal stem cells were cultured at a density of 1 ⁇ 10 5 cell/ml in T75 flask at 5% CO 2 and 37° C. and subcultured at 80% confluence.
  • the subculture was performed in a manner that the medium was removed, the stem cells were gently washed with PBS more than once, cultured in a 37° C. incubator for about 1 minute after addition of Tryple (Invitrogen), and placed in a medium containing 10% FBS fetal bovine serum (FBS) to neutralize the reaction, and then the cells were collected and centrifuged at 1,300 g for 4 minutes.
  • FBS FBS fetal bovine serum
  • the cell precipitates were resuspended in a medium containing FBS, counted, and cultured.
  • the fourth to sixth passage cells were used in the experiment.
  • Low-glucose DMEM containing 10% PBS and 1% penicillin/streptomycin was used as a medium.
  • Hemispheric tissues of white rats with induced middle cerebral artery occlusion were fragmented in 150 mg/ml DMEM medium and then centrifuged at 10,000 g for 10 minutes, and the supernatant was collected to obtain ischemic brain extracts.
  • the obtained ischemic brain extracts were plated in equal amounts and kept at ⁇ 70° C.
  • the stem cells were suspended in DMEM medium to prepare 20% ischemic brain extract, thus preparing stimulatives for ischemic preconditioning stimuli containing 20% ischemic brain extract or 20% ischemic serum.
  • the bone marrow derived mesenchymal stem cells prepared in Example 2.1 were cultured in a 60 mm culture dish in DMEM medium containing 10% FBS.
  • the stimulatives for ischemic preconditioning stimuli (20% ischemic brain extract or 20% ischemic serum) prepared in Example 2.2 were added, and then the supernatant was collected from the culture medium.
  • the supernatant was centrifuged at low speed (2,500 g, 10° C., 10 minutes) to remove impurities from the supernatant and centrifuged again at high speed (14,500 g, 10° C., 45 minutes), thus obtaining microvesicles derived from stem cells.
  • the number of the obtained microvesicle was calculated by the following formula, and the expression degree of CD105 and annexin V in each microvesicle was analyzed using a flow cytometer.
  • the number of microvesicles (n/L) (the total amount of microvesicle suspension/the amount of microvesicles used in the antibody response) ⁇ (the total amount of microvesicle diluent for flow cytometry/the amount of microvesicle diluent used for flow cytometry) ⁇ (10 6 /the total amount of serum)
  • the expression degree of CD105 and annexin V was used as a marker to determine whether the microvesicles were derived from mesenchymal stem cells, and microvesicles obtained from bone marrow-derived mesenchymal stem cells treated with knockout DEME and staurosporin A were used as controls.
  • the results of the above experiment are shown in FIG. 3 .
  • FIG. 3 it can be seen that the amount of microvesicles obtained from bone marrow-derived mesenchymal stem cells did not increase in the control groups treated with Kn DEME (knockout DEME), STS 100 nm (staurosporin A), and 20% ischemic serum (20% serum), but the amount of microvesicles significantly increased in the group treated with 20% ischemic brain extract (20% BE (whole)). Therefore, it was found that it was desirable to use the ischemic brain extract in order to increase the secretion of microvesicles.
  • Kn DEME knockout DEME
  • STS 100 nm staurosporin A
  • 20% ischemic serum 20% serum
  • microvesicles obtained by ischemic preconditioning did not cause neuronal cell death, but more than 70% neuronal cell death occurred in the group treated with NMDA. Therefore, it can be seen that the microvesicles obtained by ischemic preconditioning do not induce the death of neural stem cells and this is considered as a safe material.
  • Brain tissues collected from 14-day-old embryonic rats were gently fragmented using a narrow-bore glass pipette or dissociated to single cell level using a cell dissociation solution such as Accutase and centrifuged (500 g, 5 minutes), thus obtaining precipitated cells.
  • the obtained cells were cultured in DMEM/F12 medium containing 1XN2 supplement, 25 ng/ml bFGF, and 25 ng/ml EGF to induce neural stem cells.
  • the induced neural stem cells were subcultured such that the diameter of the neuronal cell is maintained within 100 rim.
  • Example 3.1 The neural stem cells induced in Example 3.1 were treated with the stem cell-derived microvesicles obtained in Example 2.3 by ischemic preconditioning, and the neurogenesis capabilities of the treated neural stem cells were compared.
  • Microvesicles obtained from mesenchymal stem cells without ischemic stimuli were used as a control.
  • Each experimental group was observed under an optical microscope and a confocal microscope.
  • Nestin as a marker for neural stem cells
  • DCX doublecortin
  • the neurogenesis capability did not significantly increase in neural stem cells treated with microvesicles obtained without ischemic stimuli (A), but the expression of nestin and DCX markers significantly increased in neural stem cells treated with microvesicles obtained by applying ischemic stimuli to bone marrow stem cells (B), representing the increase in neurogenesis capability.
  • Vascular endothelial cells were treated with the microvesicles (1, 3, 10, 30 ⁇ g/ml) obtained in Example 2.2 by ischemic stimuli, and the angiogenesis capabilities of vascular endothelial cells were compared.
  • Microvesicles obtained from mesenchymal stem cells without ischemic stimuli were used as a control.
  • Living cells were fluorescence-stained with Calcein AM to be used as a marker to measure the angiogenesis capability and observed under a fluorescence microscope. The results of the above experiment are shown in FIG. 6 .
  • microvesicles obtained in Example 2.3 by ischemic stimuli were injected into the ventricle of rats with ischemic stroke, and the migration distances of neural progenitor cells were compared.
  • PBS containing no microvesicles was injected into the ventricle and used as a control, and the microvesicles were fluorescence-stained with antibodies against the DCX marker for neural progenitor cells.
  • stem cell-derived microvesicles can stimulate neural progenitor cells to promote their migration.
  • microvesicles obtained in Example 2.3 by ischemic stimuli were injected into the ventricle of rats with ischemic stroke, and the degrees of angiogenesis of vascular endothelial cells were compared.
  • PBS containing no microvesicles was injected into the ventricle and used as a control, and the microvesicles were fluorescence-stained with antibodies against Von Willebrand factor (vWF), a marker for neural progenitor cells.
  • vWF Von Willebrand factor
  • the neurogenesis increased in both the ipsilateral (ipsi) and contralateral (contra) of the ventricle and, in particular, significantly increased in the contralateral of the ventricle in the experimental group treated with stem cell-derived microvesicles, compared with the normal control and the PBS-treated control group (sham). Therefore, it can be seen that the stem cell-derived microvesicles can promote the migration of neural progenitor cells and also promote angiogenesis in vascular endothelial cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
US14/238,798 2011-08-16 2012-08-14 Composition including stem cell-derived microvesicles for promoting neurogenesis Abandoned US20150045298A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20110081147 2011-08-16
KR10-2011-0081147 2011-08-26
KR1020120088778A KR101405437B1 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
KR10-2012-0088778 2012-08-14
PCT/KR2012/006478 WO2013025042A2 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006478 A-371-Of-International WO2013025042A2 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/649,842 Division US10406180B2 (en) 2011-08-16 2017-07-14 Composition including stem cell-derived microvesicles for promoting neurogenesis

Publications (1)

Publication Number Publication Date
US20150045298A1 true US20150045298A1 (en) 2015-02-12

Family

ID=47897528

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/238,798 Abandoned US20150045298A1 (en) 2011-08-16 2012-08-14 Composition including stem cell-derived microvesicles for promoting neurogenesis
US15/649,842 Active US10406180B2 (en) 2011-08-16 2017-07-14 Composition including stem cell-derived microvesicles for promoting neurogenesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/649,842 Active US10406180B2 (en) 2011-08-16 2017-07-14 Composition including stem cell-derived microvesicles for promoting neurogenesis

Country Status (5)

Country Link
US (2) US20150045298A1 (ko)
EP (1) EP2745840B1 (ko)
JP (1) JP5872041B2 (ko)
KR (1) KR101405437B1 (ko)
WO (1) WO2013025042A2 (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130554A1 (en) * 2017-01-11 2018-07-19 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
US10167448B2 (en) 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
CN111670029A (zh) * 2018-01-31 2020-09-15 首尔大学校产学协力团 源自成体干细胞的纳米囊泡及其在靶向治疗中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302468D0 (en) * 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
AU2013249786A1 (en) * 2012-04-16 2014-11-06 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
US10072247B2 (en) * 2012-10-05 2018-09-11 Samsung Life Public Welfare Foundation Composition comprising ischemic serum for promoting activation of stem cell and method for promoting activation of stem cell
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
CN105520911A (zh) * 2014-09-30 2016-04-27 重庆润泽医药有限公司 一种奥拉西坦脂质微泡及其制备方法
SG10202101358XA (en) 2015-01-26 2021-03-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
CA3003152A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US20190060367A1 (en) * 2016-03-03 2019-02-28 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EP3308795A1 (en) 2016-10-12 2018-04-18 Unicyte EV AG A composition of extracellular vesicles (evs) and medical uses thereof
US20210228643A1 (en) 2018-07-26 2021-07-29 Uniwersytet Jagiellonski N vivo delivery system of the genome dna modifying enzymes and the use thereof
KR102320800B1 (ko) * 2018-10-25 2021-11-02 사회복지법인 삼성생명공익재단 효능이 증진된 줄기세포 유래 미세소포, 이의 용도 및 효능강화 방법
US11351119B2 (en) 2018-10-25 2022-06-07 Samsung Life Public Welfare Foundation Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy
KR20230047936A (ko) * 2021-10-01 2023-04-10 주식회사 입셀 유도만능줄기세포 배양 배지 유래 성분을 포함하는 조성물 내지 이의 용도
WO2024090922A1 (ko) * 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617428A1 (en) * 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
ES2409180T3 (es) 2007-10-15 2013-06-25 Fresenius Medical Care Deutschland Gmbh Uso de microvesículas (MVS), para preparar un medicamento que tiene actividad de adyuvante en el trasplante de células endoteliales, particularmente en el tratamiento de la diabetes mediante el trasplante de islotes pancreáticos,y método relacionado
EP2211875B1 (en) * 2007-10-29 2013-05-29 Fresenius Medical Care Deutschland GmbH Use of microvesicles (mvs) derived from stem cells for preparing a medicament for endo/epithelial regeneration of damaged or injured tissues or organs, and related in vitro and in vivo methods
NZ586497A (en) * 2008-01-04 2012-07-27 Lydac Neuroscience Ltd Microvesicles
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
EP2376069B1 (en) 2008-12-19 2019-03-20 Cellerix, S.A. Microparticles comprising adipose stem cells
KR101314868B1 (ko) * 2009-07-01 2013-10-08 주식회사이언메딕스 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
JP5892939B2 (ja) * 2009-11-02 2016-03-23 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞状態をモニタリングするための方法及び間葉系幹細胞を不死化するための方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bruno et al., J Am Soc Nephrol 20: 1053-1067, April 23, 2009 *
Bruno et al., J Am Soc Nephrol, 20: 1053-1067, 2009 *
Kim et al., PLoS ONE 7(5): e37036, January 20, 2012 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10167448B2 (en) 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
WO2018130554A1 (en) * 2017-01-11 2018-07-19 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
EP4364799A3 (en) * 2017-01-11 2024-07-17 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
CN111670029A (zh) * 2018-01-31 2020-09-15 首尔大学校产学协力团 源自成体干细胞的纳米囊泡及其在靶向治疗中的应用

Also Published As

Publication number Publication date
JP2014524437A (ja) 2014-09-22
US10406180B2 (en) 2019-09-10
EP2745840A4 (en) 2015-04-22
KR101405437B1 (ko) 2014-06-11
WO2013025042A2 (ko) 2013-02-21
US20170368103A1 (en) 2017-12-28
WO2013025042A3 (ko) 2013-06-13
KR20130019356A (ko) 2013-02-26
EP2745840A2 (en) 2014-06-25
JP5872041B2 (ja) 2016-03-01
EP2745840B1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
US10406180B2 (en) Composition including stem cell-derived microvesicles for promoting neurogenesis
KR101039235B1 (ko) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
JP6519038B2 (ja) 脳梗塞治療のための多能性幹細胞
JP7514348B2 (ja) ヒアルロン酸を含む、幹細胞由来エクソソーム生成促進及び幹細胞能増強用組成物
KR20140040696A (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
KR20190094124A (ko) 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
KR20080049562A (ko) 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제
WO2018030448A1 (ja) 細胞培養用培地、及び細胞培養方法
JP2015522076A (ja) 割球様幹細胞の動員および増殖を向上させるための組成物および方法
WO2010099044A2 (en) Treatment of immunosuppression-related disorders
KR20190063453A (ko) 줄기세포 유래 엑소좀 생성 촉진용 조성물
CN116103231A (zh) 预调节间质干细胞及其制备与应用
JP7089283B2 (ja) 細胞製剤および細胞製剤の製造方法
JP6604492B2 (ja) 脳梗塞治療のための多能性幹細胞
JP7072777B2 (ja) 慢性腎障害治療のための多能性幹細胞
US20240216441A1 (en) Agent for improving cancer cachexia and method for improving cancer cachexia
KR20150091519A (ko) 다계열 분화능 세포 생성 방법
EP4026551A1 (en) Therapeutic agent for myocarditis
Jumena et al. The Effect of Hypoxic Mesenchymal Cell Secretome Administration on VEGF Levels In Type 1 Diabetes Rats Model
US20200038451A1 (en) Stem cells as an individualized maternal therapy for prevention of prematurity

Legal Events

Date Code Title Description
AS Assignment

Owner name: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, KOREA, REP

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BANG, OH YOUNG;MOON, GYEONG JOON;CHO, YEON HEE;AND OTHERS;SIGNING DATES FROM 20140220 TO 20140222;REEL/FRAME:032420/0530

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION